Teysuno(TM) (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
Teysuno(TM) (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
TOKYO, March 14, 2011 /PRNewswire/ Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission (EC) has granted marketing authorization for Teysuno(TM) (S-1), a novel …
Read more on wallstreet:online AG
Categories: Breast Cancer Treatment Tags: advanced, Authorization, cancer, European, FirstLine, gastric, marketing, receives, TeysunoTM, Therapy
Advaxis’ ‘Prokaryotic peptides for enhancing antigen immunogenicity’ European patent application allowed
Advaxis’ ‘Prokaryotic peptides for enhancing antigen immunogenicity’ European patent application allowed
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University …
Read more on News-Medical-Net
Categories: Breast Cancer Tumor Tags: 'Prokaryotic, Advaxis, allowed, antigen, application, enhancing, European, immunogenicity', Patent, peptides
European stocks extend losses to a third day on US results
European stocks extend losses to a third day on US results
European stocks retreated for a third day, led by a selloff in banks, after Citigroup and Bank of America reported revenue that missed analysts’ estimates and US consumer confidence fell more than forecast.
Read more on Brisbane Times
Do the horror stories of European state run health care mirror what to expect from Obamacare?
The numbers of beds have dropped, hospitals have merged, and specialist care has become harder to find. A 2007 survey found that in some hospitals in Geneva and Lausanne, the rates of medical mistakes had jumped by up to 40%. Long ranked as having one of the world’s top four health systems, Switzerland dropped to 8th place in a Europe-wide survey last year.
Government influence in health care may also stifle innovation, other experts warn. Bureaucracies are slow to adopt new medical technologies. In Britain and Germany, even after new drugs are approved, access to them is complicated by the fact that independent agencies must decide if they are worth buying.
When the breast cancer drug Herceptin was proven to be effective in 1998, it was available almost immediately in the U.S. But it took another four years for the U.K. to start buying it for British breast cancer patients.
http://www.usatoday.com/news/health/2009-07-05-europe-health_N.htm